News

October 8, 2014October 8, 2014

Crizotinib Treatment Recommended For ROS1-Positive Lung Cancer, According to Study

News

Crizotinib treatment has been revealed to be effective against ROS1-positive lung cancer, according to a study published in the New England Journal of Medicine. The research team presented their work at ... Read more

October 7, 2014October 7, 2014

Discovery Labs Receives $3 Million Grant for Radiation-Induced Lung Injury Therapy

News

Discovery Laboratories, a biotechnology company developing a countermeasure for the treatment of acute and chronic, late-phase radiation-induced lung injury, was granted $3.0 million from the Phase II Small Business Innovation Research Grant (SBIR), ... Read more

October 6, 2014

FDA Grants Ariad’s Lung Cancer Drug Breakthrough Therapy Status

News

The U.S. Food and Drug Administration (FDA) granted the investigational cancer drug AP26113, being developed by Ariad Pharmaceuticals, Breakthrough Therapy status. The treatment is meant for patients suffering from anaplastic lymphoma kinase positive ... Read more

October 6, 2014October 6, 2014

Dabrafenib Shows Promising Results in Non-Small-Cell Lung Cancer

News

During the European Society for Medical Oncology (ESMO) 2014 Congress held in Madrid in September, two studies were presented concerning promising therapies against subsets of Non-Small-Cell Lung Cancer (NSCLC). The study ... Read more

October 3, 2014October 3, 2014

AstraZeneca’s Iressa Receives EU Label Update For Lung Cancer Treatment

News

AstraZeneca announced a Type II update to the European label for Iressa (gefitinib) that allows doctors to identify suitable lung cancer patients for treatment with this drug even in the absence ... Read more

October 2, 2014October 2, 2014

Lung Cancer Clinical Trials Exclude Patients Due to Prior Cancer, According To Study

News

Recent research at the UT Southwestern Medical Center has found that a high percentage of patients are excluded from lung cancer clinical trials as a consequence of previous cancer history. ... Read more

October 1, 2014October 1, 2014

Nivolumab Lung Cancer Drug EMA Validation for Marketing Authorization Application

News

The first immune-checkpoint targeting drug for non-small cell lung cancer (NSCLC), Opdivo (nivolumab), was just validated by the European Medicines Agency (EMA) to review its Marketing Authorization Application (MAA), according to ... Read more

September 30, 2014September 30, 2014

Non-small Cell Lung Cancer Drug Demcizumab From OncoMed Shows Safety, Anti-Tumor Activity in Phase 1b Trials

Lung cancer News, News

OncoMed Pharmaceuticals Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), has presented safety and efficacy data from a Phase 1b clinical trial assessing the efficacy ... Read more

September 29, 2014September 29, 2014

NCI/FDA Lung Cancer Workshop Leads To LUNG-MAP And ALCHEMIST Clinical Trials

Lung cancer News, News

Two of the most innovative lung cancer focused clinical studies launched recently, the Lung Cancer Master Protocol (Lung-MAP) and the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST), ... Read more

September 25, 2014September 26, 2014

More Expensive to Treat Advanced Stage Lung Cancer than Early Screening Detection

News

The average cost of early detection of lung cancer through screening high-risk patients for the disease using low-dose computed tomography (LDCT), in addition to the average cost of curative intent treatment, such as surgery, is ... Read more